Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016 (2016), Article ID 5069678, 15 pages
http://dx.doi.org/10.1155/2016/5069678
Research Article

Evaluation of Multiple Immunoassay Technology Platforms to Select the Anti-Drug Antibody Assay Exhibiting the Most Appropriate Drug and Target Tolerance

Novimmune SA, 14 Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland

Received 13 December 2015; Revised 11 March 2016; Accepted 30 March 2016

Academic Editor: Shobha Purushothama

Copyright © 2016 Justine Collet-Brose et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J.-F. Colombel, W. J. Sandborn, P. Rutgeerts et al., “Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial,” Gastroenterology, vol. 132, no. 1, pp. 52–65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Schnitzler, H. Fidder, M. Ferrante et al., “Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort,” Gut, vol. 58, no. 4, pp. 492–500, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Moja, L. Tagliabue, S. Balduzzi et al., “Trastuzumab containing regimens for early breast cancer,” Cochrane Database of Systematic Reviews, vol. 4, Article ID CD006243, 2012. View at Google Scholar · View at Scopus
  4. L. H. Kircik and J. Q. Del Rosso, “Anti-TNF agents for the treatment of psoriasis,” Journal of Drugs in Dermatology, vol. 8, no. 6, pp. 546–559, 2009. View at Google Scholar · View at Scopus
  5. A. Seki, M. Iwamuro, M. Yoshioka et al., “Primary duodenal follicular lymphoma treated with rituximab monotherapy and followed-up for 15 years,” Acta Medica Okayama, vol. 69, no. 5, pp. 301–306, 2015. View at Google Scholar
  6. M. Deehan, S. Garcês, D. Kramer et al., “Managing unwanted immunogenicity of biologicals,” Autoimmunity Reviews, vol. 14, no. 7, pp. 569–574, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER), “Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products,” August 2014, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf.
  8. European Medicines Agency, Science Medicines Health, and Committee for Medicinal Products for Human Use (CHMP), Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use, EMA/CHMP/BMWP/86289/2010, 2012, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf.
  9. Y.-M. C. Wang, V. Jawa, and M. Ma, “Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis,” Bioanalysis, vol. 6, no. 1, pp. 79–87, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Koren, H. W. Smith, E. Shores et al., “Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products,” Journal of Immunological Methods, vol. 333, no. 1-2, pp. 1–9, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Shankar, V. Devanarayan, L. Amaravadi et al., “Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products,” Journal of Pharmaceutical and Biomedical Analysis, vol. 48, no. 5, pp. 1267–1281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. R. Mire-Sluis, Y. C. Barrett, V. Devanarayan et al., “Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products,” Journal of Immunological Methods, vol. 289, no. 1-2, pp. 1–16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Sickert, K. Kroeger, C. Zickler et al., “Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore,” Journal of Immunological Methods, vol. 334, no. 1-2, pp. 29–36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. D. Zhong, S. Dinnogen, M. Hokom et al., “Identification and inhibition of drug target interference in immunogenicity assays,” Journal of Immunological Methods, vol. 355, no. 1-2, pp. 21–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. P. A. van Schouwenburg, G. M. Bartelds, M. H. Hart, L. Aarden, G. J. Wolbink, and D. Wouters, “A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients,” Journal of Immunological Methods, vol. 362, no. 1-2, pp. 82–88, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Patton, M. C. Mullenix, S. J. Swanson, and E. Koren, “An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen,” Journal of Immunological Methods, vol. 304, no. 1-2, pp. 189–195, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. H. W. Smith, A. Butterfield, and D. Sun, “Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA,” Regulatory Toxicology and Pharmacology, vol. 49, no. 3, pp. 230–237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Mikulskis, D. Yeung, M. Subramanyam, and L. Amaravadi, “Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development,” Journal of Immunological Methods, vol. 365, no. 1-2, pp. 38–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. D. K. Weeraratne, J. Lofgren, S. Dinnogen, S. J. Swanson, and Z. D. Zhong, “Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference,” Journal of Immunological Methods, vol. 396, no. 1-2, pp. 44–55, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER), Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins, 2009, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm192750.pdf.
  21. J. J. Haringman, D. M. Gerlag, T. J. M. Smeets et al., “A randomized controlled trial with an anti-CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 8, pp. 2387–2392, 2006. View at Publisher · View at Google Scholar · View at Scopus